About CytoPherx
CytoPherx is a company based in Ann Arbor (United States) founded in 1994.. CytoPherx has raised $47.69 million across 3 funding rounds from investors including Early Stage Partners, ONSET Ventures and Capital Midwest Fund. CytoPherx has completed 1 acquisition, including Immunocept Medical Products. CytoPherx operates in a competitive market with competitors including Hemotune, Medcura, ExThera Medical, Lindis Blood Care and Arteriocyte, among others.
- Headquarter Ann Arbor, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$47.69 M (USD)
in 3 rounds
-
Latest Funding Round
$34 M (USD), Series B
Jan 06, 2012
-
Investors
Early Stage Partners
& 5 more
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of CytoPherx
CytoPherx has successfully raised a total of $47.69M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $34 million completed in January 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $34.0M
-
First Round
First Round
(02 Nov 2009)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2012 | Amount | Series B - CytoPherx | Valuation | Early Stage Partners , ONSET Ventures |
|
| Jun, 2010 | Amount | Series A - CytoPherx | Valuation |
investors |
|
| Nov, 2009 | Amount | Unspecified - CytoPherx | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in CytoPherx
CytoPherx has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include Early Stage Partners, ONSET Ventures and Capital Midwest Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments in US tech companies are made.
|
Founded Year | Domain | Location | |
|
Early stage VC firm investing in the US
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by CytoPherx
CytoPherx has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Immunocept Medical Products. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Blood filtration therapy for severe sepsis is developed.
|
1999 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - CytoPherx
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cytopherx Comparisons
Competitors of CytoPherx
CytoPherx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Hemotune, Medcura, ExThera Medical, Lindis Blood Care and Arteriocyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of a device for blood purification
|
|
| domain | founded_year | HQ Location |
Developer of the device for controlling bleeding
|
|
| domain | founded_year | HQ Location |
Medical devices for the rapid treatment of bloodstream infections and pathogen-reduction in blood banking
|
|
| domain | founded_year | HQ Location |
Innovative solutions for safer blood transfusions are developed.
|
|
| domain | founded_year | HQ Location |
Devices to facilitate blood component and bone marrow transplant
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about CytoPherx
When was CytoPherx founded?
CytoPherx was founded in 1994 and raised its 1st funding round 15 years after it was founded.
Where is CytoPherx located?
CytoPherx is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.
Who is the current CEO of CytoPherx?
Charles Fisher is the current CEO of CytoPherx.
Is CytoPherx a funded company?
CytoPherx is a funded company, having raised a total of $47.69M across 3 funding rounds to date. The company's 1st funding round was a Unspecified of $2M, raised on Nov 02, 2009.
What does CytoPherx do?
Founded in 1994 as Nephrion and renamed CytoPherx in 2009, the company operates in the medical device sector from Ann Arbor, United States. Systems are designed to sequester and deactivate leucocytes in the circulatory system, utilizing hollow fiber dialysis filters. Targets include acute renal failure, end-stage renal disease, and inflammation from cardiopulmonary bypass surgery. Leadership is provided by CEO Charles Fisher.
Who are the top competitors of CytoPherx?
CytoPherx's top competitors include Medcura, ExThera Medical and Lindis Blood Care.
How many acquisitions has CytoPherx made?
CytoPherx has made 1 acquisition, including Immunocept Medical Products.
Who are CytoPherx's investors?
CytoPherx has 6 investors. Key investors include Early Stage Partners, ONSET Ventures, Capital Midwest Fund, Kaiser Permanente Ventures, and Emergent Medical Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.